News | February 08, 2022
Granules India Q3FY22 PAT at Rs 100.88 cr.
Granules India has reported consolidated financial results for the period ended December 31, 2021
Granules India has reported consolidated financial results for the period ended December 31, 2021
The partnership includes multiple collaboration areas and is an important milestone for bringing cost-competitive biobased products to the market, with applications in the pharmaceutical, agricultural, cosmetics and personal care, and automotive industries
The campaign aims to bring back focus on leprosy case detection, treatment and rehabilitation; especially in the context of neglect brought in by Covid-19 pandemic
Rahul has spent almost 17 years at Boston Consulting Group (BCG) where he has led the Health Care & Life Sciences practice
The target demographic will be those between the ages of 30 and 65 years
The acquisition will allow Dr. Reddy's to build on Nimbus Health's strengths and introduce medical cannabis-based medicines as a promising treatment option for patients
Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy
The CAS SciFinder Discovery Platform expansion unlocks human-indexed insights from journals and patents in over 50 languages dating back to 1957 and 70 million biosequences curated by CAS scientists
A National Tele Mental Health Programme is being launched to address mental health issues. We spoke to healthcare industry leaders who shared their outlook
Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021
Subscribe To Our Newsletter & Stay Updated
